Peregrine Pharmaceuticals (NASDAQ:PPHM) took a major hit in September after admitting a trial data mix-up for its top drug candidate bavituximab. Since that day, shares had fallen around 80%. Today however, shares were back on the rise, up a healthy 26% (from a much lower base). In this video, Motley Fool health care analyst Brenton Flynn discusses what could be driving share prices today.
After a major September tumble, Peregrine jumped 26% today.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.